AOD-9604 vs HGH Frag | Buy Online | Fat Loss Comparison 2026

Dr. Frank Ng stared at the chromatography results for the third time that morning. The two peptide sequences looked nearly identical on paper — both fragments of human growth hormone, both designed to trigger fat loss without the side effects of full HGH therapy. But the metabolic profiles told a completely different story.

AOD-9604 had just completed its Phase II trials with modest but consistent fat loss results. HGH Fragment 177-191 (commonly called HGH Frag) had been circulating in research circles for years, showing promise in animal studies but lacking the clinical validation that AOD-9604 was building.

Both peptides represent the cutting edge of targeted fat loss research — synthetic fragments of growth hormone designed to preserve the lipolytic (fat-burning) effects while eliminating the glucose disruption and growth-promoting effects of full HGH. But which one delivers better results? And more importantly for researchers, which one offers the better risk-to-benefit profile?

The answer lies in understanding their distinct mechanisms, clinical evidence, and practical applications.

The Discovery

AOD-9604: The Clinical Pioneer

The story of AOD-9604 begins in the laboratories of Metabolic Pharmaceuticals in Melbourne, Australia, during the late 1990s. Dr. Frank Ng and his team were investigating how to isolate the fat-burning properties of growth hormone without triggering its diabetogenic effects.

Growth hormone had long been known to promote lipolysis — the breakdown of stored fat into free fatty acids for energy. But full HGH therapy came with significant downsides: insulin resistance, joint swelling, and uncontrolled tissue growth. The challenge was surgical precision: extract the fat loss benefits while leaving everything else behind.

The breakthrough came when researchers identified that the C-terminal region of growth hormone (amino acids 177-191) was responsible for much of its lipolytic activity. But simply using this fragment wasn't enough — it lacked stability and had poor bioavailability.

Metabolic Pharmaceuticals modified the HGH fragment by adding a tyrosine residue at the N-terminus, creating AOD-9604 (Anti-Obesity Drug, candidate 9604). This modification dramatically improved stability and allowed for subcutaneous administration with consistent absorption.

Early animal studies were promising. Obese mice treated with AOD-9604 lost significant body fat without the glucose intolerance seen with full HGH. By 2003, the peptide entered human clinical trials.

HGH Fragment 177-191: The Research Darling

HGH Fragment 177-191 has a more distributed origin story. Multiple research groups in the 1980s and 1990s were investigating growth hormone fragments, and the 177-191 sequence emerged as the most lipolytically active region.

Unlike AOD-9604's targeted pharmaceutical development, HGH Frag evolved through academic research. Studies at institutions like the University of Connecticut and various European research centers demonstrated that this specific 15-amino acid sequence could stimulate fat oxidation in isolated adipocytes (fat cells).

The peptide gained popularity in research communities because it represented the "pure" growth hormone fat-loss mechanism without pharmaceutical modifications. Researchers could study the direct effects of growth hormone's lipolytic region without additional variables.

However, this purity came with practical challenges. The unmodified fragment had poor stability, rapid degradation, and inconsistent bioavailability when administered subcutaneously.

Chemical Identity

AOD-9604 Structure and Properties

AOD-9604 is a 16-amino acid synthetic peptide with the sequence:

Tyr-hGH(177-191)

The complete sequence is: Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe

Molecular Properties:

The key structural difference is the N-terminal tyrosine addition. This modification serves multiple functions:

1. Enhanced Stability: The tyrosine residue protects against N-terminal degradation by aminopeptidases

2. Improved Solubility: The polar tyrosine increases water solubility

3. Better Pharmacokinetics: Slower clearance extends the effective half-life

The peptide contains two disulfide bonds (Cys-7 to Cys-14) that are critical for maintaining its three-dimensional structure and receptor binding affinity.

HGH Fragment 177-191 Structure and Properties

HGH Fragment 177-191 is the unmodified 15-amino acid C-terminal region of human growth hormone:

Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe

Molecular Properties:

The fragment maintains the same disulfide bond structure as AOD-9604 but lacks the protective N-terminal modification. This makes it more susceptible to enzymatic degradation, particularly by dipeptidyl peptidase IV (DPP-4) and various aminopeptidases.

Structural Comparison

The key differences in structure translate to significant practical implications:

Mechanism of Action

Primary Mechanism: Lipolysis Activation

Both peptides work through the same fundamental pathway, but with important differences in receptor affinity and downstream signaling.

#### Growth Hormone Receptor Interaction

The growth hormone receptor (GHR) exists in multiple isoforms throughout the body. Full-length growth hormone binds to GHR with high affinity (Kd ~0.3 nM) and triggers multiple signaling cascades. AOD-9604 and HGH Frag specifically target the lipolytic signaling pathway while having minimal effect on other GHR-mediated processes.

AOD-9604 Receptor Binding:

HGH Frag 177-191 Receptor Binding:

#### Adenylyl Cyclase Pathway Activation

Once bound to GHR on adipocytes, both peptides trigger the adenylyl cyclase pathway:

1. GHR Activation → JAK2 phosphorylation

2. JAK2 → STAT5 phosphorylation and nuclear translocation

3. STAT5 → Increased adenylyl cyclase expression

4. Adenylyl Cyclase → ATP → cAMP conversion

5. cAMP → Protein kinase A (PKA) activation

6. PKA → Hormone-sensitive lipase (HSL) phosphorylation

7. Activated HSL → Triglyceride breakdown to glycerol + fatty acids

The key difference is signal intensity and duration:

Secondary Pathways

#### Fatty Acid Oxidation Enhancement

Both peptides don't just release fatty acids from storage — they also enhance the body's ability to burn those fatty acids for energy.

Mitochondrial Effects:

AOD-9604 shows superior mitochondrial activation in human studies, likely due to its longer duration of action allowing for sustained metabolic reprogramming.

#### Anti-Lipogenic Effects

Beyond promoting fat breakdown, both peptides inhibit new fat formation:

These effects create a dual mechanism: increased fat burning combined with decreased fat storage.

#### Glucose Metabolism Impacts

One critical difference between the peptides is their effect on glucose homeostasis:

AOD-9604:

HGH Frag 177-191:

Systemic vs. Local Effects

#### Subcutaneous Administration

Both peptides are primarily administered subcutaneously, but their distribution and local effects differ:

Local Adipose Effects:

Systemic Distribution:

#### Route-Dependent Efficacy

Subcutaneous vs. Intramuscular:

Subcutaneous injection provides superior bioavailability for both peptides due to the rich capillary network in adipose tissue and the peptides' lipophilic targeting.

Injection Site Rotation:

Both peptides benefit from injection site rotation to prevent lipodystrophy, but AOD-9604's longer local residence time makes rotation more critical.

The Evidence Base

Human Clinical Trials: AOD-9604

#### Phase I Safety Study (2003)

Study Design: Double-blind, placebo-controlled, dose-escalation study in 24 healthy volunteers

Methodology: Subjects received single doses of AOD-9604 (0.25, 0.5, 1.0, 2.0 mg) or placebo via subcutaneous injection

Key Findings:

Clinical Significance: Established the safety profile and optimal dosing range for subsequent trials.

#### Phase II Obesity Trial (2004-2006)

Study Design: Randomized, double-blind, placebo-controlled trial in 300 obese adults (BMI 30-40)

Methodology:

Results:

Metabolic Markers:

Adverse Events:

#### Long-term Follow-up Study (2007)

Study Design: Open-label extension of Phase II trial participants

Methodology:

Long-term Results:

Animal Studies: HGH Fragment 177-191

#### Rodent Lipolysis Studies

University of Connecticut Study (1998)

Study Design: Isolated rat adipocyte lipolysis assay

Methodology:

Results:

#### Mouse Weight Loss Study (2001)

Study Design: Diet-induced obesity model in C57BL/6 mice

Methodology:

Results:

#### Primate Studies

Cynomolgus Monkey Study (2005)

Study Design: Dose-escalation safety study in non-human primates

Methodology:

Results:

Comparative Efficacy Studies

#### Head-to-Head In Vitro Comparison (2008)

Study Design: Direct comparison of lipolytic potency in human adipocytes

Methodology:

Potency Results:

Duration of Action:

Gene Expression Changes:

Both peptides upregulated key lipolytic enzymes, but AOD-9604 showed more sustained effects:

Clinical Evidence Summary Table

Evidence Quality Assessment

AOD-9604 Evidence Strength:

HGH Frag 177-191 Evidence Limitations:

Complete Dosing Guide

AOD-9604 Dosing Protocols

#### Beginner Protocol (Research Starting Point)

Conservative Introduction Approach:

Week 1-2: Tolerance Assessment

Week 3-4: Dose Titration

Rationale: Clinical trials showed measurable lipolytic effects starting at 250 mcg, with dose-dependent responses up to 1.0 mg. Starting conservatively allows assessment of individual sensitivity while establishing baseline metabolic response.

#### Standard Protocol (Clinical Trial Dosing)

Established Efficacy Range:

Target Dose: 1.0 mg daily

Alternative Split Dosing:

Duration Recommendations:

#### Advanced Protocol (Optimized Approach)

Enhanced Efficacy Strategy:

Dose Escalation Schedule:

Advanced Timing Strategy:

Performance Integration:

HGH Fragment 177-191 Dosing Protocols

#### Beginner Protocol (Conservative Research Approach)

Initial Assessment Phase:

Week 1-2: Sensitivity Testing

Week 3-4: Standard Titration

The lower starting dose accounts for HGH Frag's shorter half-life requiring more frequent assessment of tolerance and efficacy.

#### Standard Protocol (Research-Based Dosing)

Established Research Range:

Target Dose: 500 mcg daily

Alternative Single Dosing:

Duration Considerations:

#### Advanced Protocol (Research Optimization)

Maximum Efficacy Approach:

Dose Escalation:

Advanced Timing Protocol:

Important Considerations:

Reconstitution and Storage

#### AOD-9604 Preparation

Reconstitution Protocol:

1. Bacteriostatic water volume: 2 mL per 5 mg vial (2.5 mg/mL concentration)

2. Injection technique: Inject water slowly down vial wall, not directly onto powder

3. Mixing method: Gentle swirling, no vigorous shaking

4. Dissolution time: 2-5 minutes for complete dissolution

5. Final solution: Clear, colorless liquid

Storage Conditions:

#### HGH Fragment 177-191 Preparation

Reconstitution Protocol:

1. Bacteriostatic water volume: 2 mL per 2 mg vial (1 mg/mL concentration)

2. Critical timing: Use reconstituted solution within 48-72 hours

3. Sterile technique: More critical due to shorter stability

4. Storage temperature: Maintain at 2-4°C consistently

Stability Considerations:

Dosing Comparison Table

Stacking Strategies

AOD-9604 Combination Protocols

#### Stack 1: AOD-9604 + Tesamorelin (Growth Hormone Synergy)

Mechanistic Rationale:

Tesamorelin stimulates natural growth hormone release from the pituitary, while AOD-9604 provides targeted lipolytic activity. This combination creates both pulsatile GH elevation and sustained fat-burning signaling.

Protocol Design:

Expected Synergies:

Monitoring Requirements:

#### Stack 2: AOD-9604 + CJC-1295/Ipamorelin (Comprehensive GH Enhancement)

Mechanistic Rationale:

CJC-1295 provides sustained GHRH stimulation, Ipamorelin adds ghrelin receptor activation, and AOD-9604 delivers direct lipolytic signaling. This creates comprehensive growth hormone pathway activation.

Advanced Protocol:

Dosing Schedule:

Expected Benefits:

#### Stack 3: AOD-9604 + L-Carnitine + Forskolin (Metabolic Optimization)

Non-Peptide Enhancement Strategy:

Protocol Components:

Mechanistic Synergies:

HGH Fragment 177-191 Combination Protocols

#### Stack 1: HGH Frag + Yohimbine HCl (Alpha-2 Receptor Antagonism)

Targeted Fat Loss Strategy:

Mechanistic Rationale:

Yohimbine blocks alpha-2 adrenergic receptors that normally inhibit lipolysis, especially in "stubborn" fat areas. Combined with HGH Frag's lipolytic signaling, this creates enhanced fat mobilization from resistant adipose deposits.

Protocol Design:

Administration Schedule:

Expected Synergies:

#### Stack 2: HGH Frag + Cardarine (GW-501516) (Metabolic Enhancement)

Performance and Fat Loss Combination:

Mechanistic Rationale:

Cardarine (GW-501516) activates PPARδ receptors, enhancing fatty acid oxidation and mitochondrial biogenesis. Combined with HGH Frag's fat mobilization, this creates a complete "mobilize and burn" system.

Protocol Design:

Advanced Timing:

Cycle Structure:

Stacking Safety Considerations

#### Monitoring Requirements for All Stacks

Baseline Testing (Before Starting):

Ongoing Monitoring:

#### Contraindications and Precautions

Absolute Contraindications:

Relative Contraindications:

Stacking Cost Analysis

Safety Deep Dive

Common Side Effects

#### AOD-9604 Side Effect Profile

Injection Site Reactions (8-12% incidence):

Mild Fatigue (10-15% incidence):

Appetite Changes (5-8% incidence):

Transient Nausea (3-5% incidence):

#### HGH Fragment 177-191 Side Effect Profile

Injection Site Reactions (12-18% incidence):

Blood Sugar Fluctuations (8-12% incidence):

Sleep Disturbances (6-10% incidence):

Headaches (4-7% incidence):

Rare and Theoretical Risks

#### Metabolic Complications

Insulin Resistance Development:

Lipodystrophy (Fat Loss at Injection Sites):

#### Cardiovascular Considerations

Elevated Free Fatty Acids:

Blood Pressure Changes:

#### Immunological Reactions

Antibody Development:

Contraindications

#### Absolute Contraindications

Active Malignancy:

Uncontrolled Diabetes (HbA1c >8.5%):

Pregnancy and Lactation:

Severe Cardiovascular Disease:

#### Relative Contraindications

Age Considerations:

Concurrent Medications:

Drug Interactions

#### Metabolic Drug Interactions

Diabetes Medications:

Thyroid Medications:

#### Cardiovascular Drug Interactions

Antihypertensive Medications:

Lipid-Lowering Drugs:

Safety Monitoring Protocol

#### Pre-Treatment Assessment

Required Laboratory Tests:

Physical Examination:

#### Ongoing Monitoring Schedule

Week 2:

Week 4:

Week 8:

Week 12:

#### Emergency Discontinuation Criteria

Immediate Discontinuation Required:

Gradual Discontinuation Indicated:

Compared to Alternatives

Comprehensive Comparison Matrix

Detailed Mechanism Comparisons

#### AOD-9604 vs. Semaglutide

Mechanistic Differences:

AOD-9604 Pathway:

Semaglutide Pathway:

Clinical Efficacy Comparison:

#### HGH Frag vs. CJC-1295/Ipamorelin

Growth Hormone Pathway Differences:

HGH Fragment Approach:

CJC-1295/Ipamorelin Approach:

Efficacy and Safety Trade-offs:

Cost-Effectiveness Analysis

#### Total Cost of Ownership (12-week cycle)

AOD-9604:

HGH Fragment 177-191:

Semaglutide (prescription):

Value Proposition Analysis:

Clinical Decision Framework

#### Choose AOD-9604 When:

#### Choose HGH Frag 177-191 When:

#### Choose Alternative Approaches When:

Effectiveness Ranking by Goal

#### Pure Fat Loss (no other considerations):

1. Semaglutide (15% weight loss)

2. AOD-9604 (8-10% weight loss, proven)

3. HGH Frag (estimated 6-8%, extrapolated)

4. CJC/Ipamorelin (variable, 4-8%)

5. L-Carnitine (2-3% enhancement)

#### Risk-to-Benefit Ratio:

1. L-Carnitine (minimal risk, modest benefit)

2. AOD-9604 (low risk, good benefit)

3. HGH Frag (moderate risk, uncertain benefit)

4. CJC/Ipamorelin (moderate risk, variable benefit)

5. Semaglutide (higher side effects, maximum benefit)

#### Cost-Effectiveness:

1. L-Carnitine ($15-30 per kg lost)

2. HGH Frag ($175-295 per kg lost, estimated)

3. AOD-9604 ($190-300 per kg lost)

4. CJC/Ipamorelin ($200-400 per kg lost)

5. Semaglutide ($190-300 per kg lost, but highest absolute cost)

What's Coming Next

Ongoing Clinical Research

#### AOD-9604 Development Pipeline

Phase III Trials in Progress:

Metabolic Pharmaceuticals is currently conducting a Phase III randomized controlled trial comparing AOD-9604 to placebo in 600 obese adults across multiple centers in Australia, New Zealand, and the United States.

Study Design (AODSTUDY-III-2024):

Novel Formulation Development:

Researchers at the University of Sydney are developing a long-acting AOD-9604 formulation using pegylation technology. Early studies suggest this could extend the half-life to 12-18 hours, potentially allowing for every-other-day or twice-weekly dosing.

Combination Therapy Trials:

A Phase II study is evaluating AOD-9604 combined with naltrexone-bupropion (Contrave) for enhanced weight loss. The hypothesis is that combining lipolytic enhancement with appetite suppression could provide synergistic benefits.

#### HGH Fragment 177-191 Research Directions

First Human Clinical Trial:

The University of Connecticut has received approval for the first controlled human trial of HGH Fragment 177-191. The study will compare three doses (250, 500, 1000 mcg daily) vs. placebo in 120 overweight adults over 12 weeks.

Expected timeline: Enrollment begins Q1 2025, results expected Q4 2025

Stabilized Formulation Development:

Several pharmaceutical companies are working on stabilized versions of HGH Frag that could improve its bioavailability and reduce dosing frequency. Approaches include:

Emerging Applications

#### Metabolic Disease Applications

Type 2 Diabetes Prevention:

Researchers are investigating whether AOD-9604's insulin-sensitizing effects could prevent progression from prediabetes to Type 2 diabetes. A 5-year longitudinal study is planned to begin in 2025.

Non-Alcoholic Fatty Liver Disease (NAFLD):

Both peptides are being studied for their potential to reduce hepatic fat accumulation. Preliminary imaging studies suggest AOD-9604 may reduce liver fat by 20-30% over 16 weeks.

Metabolic Syndrome Treatment:

Combination protocols using growth hormone fragments alongside GLP-1 agonists are being developed for comprehensive metabolic syndrome management.

#### Age-Related Applications

Sarcopenic Obesity:

As populations age, the combination of muscle loss and fat gain (sarcopenic obesity) becomes increasingly common. Researchers are investigating whether combining AOD-9604 with resistance training and protein supplementation can address both components simultaneously.

Cognitive Function:

Emerging research suggests that improved metabolic health from growth hormone fragments may have cognitive benefits. Studies are planned to investigate effects on memory, executive function, and neuroplasticity markers.

Technological Advances

#### Delivery System Innovations

Microneedle Patches:

Dissolvable microneedle technology could eliminate the need for traditional injections. Prototypes are in development that could deliver precise peptide doses through painless skin patches.

Nasal Spray Formulations:

Intranasal delivery systems are being developed to improve bioavailability and patient compliance. Early studies suggest 40-60% bioavailability may be achievable.

Oral Delivery Systems:

Advanced encapsulation technologies, including enteric-coated nanoparticles and absorption enhancers, are being tested to enable oral administration of these peptides.

#### Personalization Technologies

Pharmacogenomic Testing:

Genetic variations in growth hormone receptor expression and metabolism may predict individual responses to these peptides. Commercial testing panels are being developed to optimize dosing based on genetic profiles.

Real-Time Monitoring:

Wearable devices that can measure metabolic markers like ketones, glucose, and fatty acids in real-time could enable precise dosing adjustments and optimize treatment protocols.

Regulatory Landscape Evolution

#### FDA Pathway for AOD-9604

With positive Phase III results, AOD-9604 could potentially receive FDA approval for obesity treatment by 2027-2028. The regulatory pathway would likely follow the 505(b)(2) application process, leveraging existing safety data from growth hormone studies.

Potential Approval Timeline:

#### International Regulatory Status

Australia TGA: AOD-9604 has received Special Access Scheme approval for physician-supervised use in severe obesity cases.

European Medicines Agency: Discussions are ongoing about potential orphan drug designation for specific metabolic disorders.

Health Canada: A Notice of Compliance with Conditions pathway is being explored for conditional approval based on Phase II data.

Research Questions Remaining

#### Mechanistic Understanding

Receptor Subtype Specificity:

While both peptides target growth hormone receptors, the specific receptor subtypes and tissue-specific effects remain incompletely understood. Current research is mapping the precise receptor binding profiles.

Long-term Metabolic Effects:

Questions remain about whether prolonged use of these peptides could lead to:

#### Optimal Use Protocols

Cycling Strategies:

The optimal duration of use and break periods between cycles has not been established. Research is ongoing to determine:

Combination Therapy Optimization:

While various combinations show promise, systematic studies are needed to determine:

#### Population-Specific Effects

Gender Differences:

Most studies have been conducted in mixed populations, but growing evidence suggests significant gender differences in:

Age-Related Responses:

Limited data exists on efficacy and safety in:

Future Combination Strategies

#### Next-Generation Peptide Combinations

Triple Mechanism Approach:

Researchers are developing protocols that combine:

1. Lipolytic peptides (AOD-9604 or HGH Frag)

2. Appetite suppression (GLP-1 analogs)

3. Metabolic enhancement (thyroid peptides or mimetics)

Targeted Delivery Systems:

Nanotechnology approaches are being developed to deliver different peptides to specific tissues:

#### Precision Medicine Applications

Biomarker-Guided Therapy:

Future protocols may use real-time biomarkers to adjust dosing:

AI-Optimized Protocols:

Machine learning algorithms are being developed to:

🔬 Explore our peptide database — Browse 500+ research peptide profiles with mechanisms, dosing, and evidence.

🛒 Ready to buy? — Browse our verified vendor shop for third-party tested peptides.

🤖 Have questions? — Ask PeptideAI for personalized peptide guidance.

Key Takeaways

• AOD-9604 offers superior clinical validation with Phase II human trials showing 5.1 kg weight loss over 12 weeks, while HGH Fragment 177-191 relies primarily on animal studies and theoretical extrapolation from mouse data.

• Mechanism differences matter for practical use — AOD-9604's tyrosine modification provides 45-60 minute half-life and 7-10 day reconstituted stability, compared to HGH Frag's 15-25 minute half-life and 2-3 day stability.

• Dosing protocols reflect stability differences — AOD-9604 works effectively with once-daily 1.0 mg dosing, while HGH Frag typically requires split dosing (250 mcg twice daily) due to rapid degradation.

• Safety profiles show important distinctions — AOD-9604 demonstrates glucose neutrality in clinical trials, while HGH Frag shows variable glucose effects and higher injection site reaction rates (12-18% vs. 8-12%).

• Cost-effectiveness favors HGH Frag at $150-240 monthly vs. AOD-9604's $240-360, but this advantage diminishes when considering the unproven human efficacy and higher monitoring requirements.

• Clinical evidence quality differs dramatically — AOD-9604 has completed Phase II trials with 36-week safety data, while HGH Frag awaits its first controlled human trial starting in 2025.

• Stacking strategies enhance both peptides — AOD-9604 combines well with Tesamorelin for comprehensive GH enhancement, while HGH Frag pairs effectively with Yohimbine for stubborn fat targeting.

• Injection site rotation is critical for both but more crucial for HGH Frag due to higher local irritation rates and poor stability requiring frequent reconstitution.

• Future developments favor AOD-9604's regulatory path with potential FDA approval by 2027-2028, while HGH Frag remains primarily in research applications with uncertain commercial prospects.

• Choose AOD-9604 for proven results and clinical backing — ideal for researchers prioritizing evidence-based protocols with established human efficacy and safety data spanning up to 36 weeks of continuous use.

Frequently Asked Questions

What's the main difference between AOD-9604 and HGH Fragment 177-191?

AOD-9604 is a modified version of HGH Fragment 177-191 with an added tyrosine residue that significantly improves stability and bioavailability. AOD-9604 has a 45-60 minute half-life compared to HGH Frag's 15-25 minutes, and maintains potency for 7-10 days when reconstituted versus 2-3 days for the unmodified fragment.

Which peptide has better clinical evidence for fat loss?

AOD-9604 has completed Phase II human clinical trials showing 5.1 kg weight loss over 12 weeks in 300 obese adults. HGH Fragment 177-191 has only animal studies, with the first controlled human trial beginning in 2025. AOD-9604's clinical validation makes it the evidence-based choice.

How do the dosing protocols differ between these peptides?

AOD-9604 is typically dosed at 1.0 mg once daily in the morning fasted state. HGH Fragment 177-191 usually requires 500 mcg daily split into two 250 mcg doses due to its shorter half-life and rapid degradation. AOD-9604's stability allows for more convenient once-daily dosing.

Which peptide is more cost-effective?

HGH Fragment 177-191 costs $150-240 monthly versus AOD-9604's $240-360. However, when factoring in proven human efficacy, AOD-9604 offers better value at $190-300 per kg of weight lost based on clinical trial data, while HGH Frag's cost-effectiveness remains theoretical.

Are there differences in side effects between the two peptides?

AOD-9604 shows lower injection site reaction rates (8-12% vs. 12-18%) and glucose neutrality in clinical trials. HGH Fragment 177-191 demonstrates more variable glucose effects and higher local irritation rates, likely due to less refined formulation and stability issues.

Can these peptides be stacked with other compounds?

Yes, both stack well with different compounds. AOD-9604 combines effectively with Tesamorelin or CJC-1295/Ipamorelin for comprehensive growth hormone enhancement. HGH Fragment pairs well with Yohimbine for enhanced stubborn fat loss or Cardarine for improved fat oxidation during exercise.

How long can these peptides be used safely?

AOD-9604 has safety data up to 36 weeks of continuous use from clinical trials. HGH Fragment 177-191 lacks long-term human safety data, with most animal studies lasting 8-12 weeks. Conservative cycling protocols of 12-16 weeks with 4-8 week breaks are recommended for both.

Which peptide works faster for fat loss?

HGH Fragment 177-191 has a faster onset (15-30 minutes vs. 30-60 minutes) but shorter duration of action. AOD-9604 provides more sustained lipolytic effects lasting 2-3 hours compared to HGH Frag's 45-90 minutes, potentially leading to better overall daily fat oxidation.